Blueshift Asset Management LLC Takes $176,000 Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Blueshift Asset Management LLC acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,269 shares of the biotechnology company’s stock, valued at approximately $176,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock worth $865,000 after buying an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock valued at $954,000 after acquiring an additional 700 shares during the last quarter. Mutual of America Capital Management LLC raised its position in ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock valued at $614,000 after purchasing an additional 751 shares in the last quarter. Maryland State Retirement & Pension System lifted its stake in ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after purchasing an additional 897 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $19.80 on Friday. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of 70.71 and a beta of 0.60. The company has a 50-day simple moving average of $16.76 and a two-hundred day simple moving average of $18.04. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.64.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.